Log in or create an account for full access to this data.
Create a free account or log in to use this tool.
Create a free account or log in to explore DrugBank data.
Gedatolisib is a pan-PI3K and mTORC1/2 inhibitor used with fulvestrant, with or without palbociclib, for HR-positive, HER2-negative advanced breast cancer without a PIK3CA mutation following endocrine therapy. Gedatolisib is a kinase inhibitor that blocks all four class I PI3K isoforms together with both mTOR complexes, mTORC1 and mTORC2, producing downstream inhibition of multiple effectors including AKT.
- Mechanism
- Curator reviewed · 3 references
Gedatolisib is a kinase inhibitor of the class I PI3K isoforms (α, β, δ, γ) and of the mTOR complexes mTORC1 and mTORC2, resulting in downstream inhibition of multiple effectors, including AKT. In estrogen receptor (ER)-positive breast cancer cell lines and xenograft models harboring wild-type or mutant PIK3CA, gedatolisib induced apoptosis and anti-proliferative effects in vitro and reduced tumor cell growth in vivo. In a human ER-positive breast cancer xenograft model harboring a PIK3CA mutation, gedatolisib combined with palbociclib and fulvestrant increased tumor growth inhibition compared with each treatment alone or the doublet combinations.
- Primary indication
- Gedatolisib is a kinase inhibitor indicated in combination with fulvestrant, with or without palbociclib, for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic...Curator reviewed · 2 structured indications
- Formula / weight
- C32H41N9O4 · 615.739 g/mol (avg)
- First approval
- United States, 2026
- Code names
- PF-05212384 · PKI-587
- Brand names
- Revtorpyk
Resolves to
DWZAEMINVBZMHQ-UHFFFAOYSA-NSMILESCN(C)C1CCN(CC1)C(=O)C1=CC=C(NC(=O)NC2=CC=C(C=C2)C2=NC(=NC(=N2)N2CCOCC2)N2CCOCC2)C=C1What you can answer from here — as of November 02, 2026
Which drugs share a target with Gedatolisib, and which of those have an active Phase 3 trial?